(Q42652476)

4 November 2017

High efficacy of erlotinib in Taiwanese NSCLC patients in an expanded access program study previously treated with chemotherapy (English)

1 reference

non-small-cell lung carcinoma

4 November 2017

1 reference

1 reference

1 reference

Reury-Perng Perng

1

1 reference

4 November 2017

Chih-Hsin Yang

2

1 reference

4 November 2017

Yuh-Min Chen

3

1 reference

4 November 2017

Gee-Chen Chang

4

1 reference

4 November 2017

Meng-Chih Lin

5

1 reference

4 November 2017

Ruey-Kuen Hsieh

6

1 reference

4 November 2017

Nei-Min Chu

7

1 reference

4 November 2017

Ruay-Sheng Lai

8

1 reference

4 November 2017

Wu-Chou Su

9

1 reference

4 November 2017

Chao-Jung Tsao

10

1 reference

4 November 2017

Te-Chun Hsia

11

1 reference

4 November 2017

Hao-Cheng Chen

12

1 reference

4 November 2017

Chih-Hung Chen

13

1 reference

4 November 2017

Ming-Shyan Huang

14

1 reference

4 November 2017

Jui-Long Wang

15

1 reference

4 November 2017

Ming-Lin Ho

16

1 reference

4 November 2017

Chih-Yuan Chung

17

1 reference

4 November 2017

Chong-Jen Yu

18

1 reference

4 November 2017

Wen-Cheng Chang

19

1 reference

4 November 2017

Han-Pin Kuo

20

1 reference

4 November 2017

Chih-Teng Yu

21

1 reference

4 November 2017

Zhong-Zhe Lin

22

1 reference

4 November 2017

Woei-Yau Kao

23

1 reference

4 November 2017

18 April 2008

1 reference

4 November 2017

1 reference

4 November 2017

62

1 reference

4 November 2017

1

1 reference

4 November 2017

78-84

1 reference

Gefitinib plus best supportive care in previously treated patients with refractory advanced non-small-cell lung cancer: results from a randomised, placebo-controlled, multicentre study (Iressa Survival Evaluation in Lung Cancer)

4 November 2017

1 reference

5 June 2022

https://opencitations.net/index/coci/api/v1/references/10.1016/J.LUNGCAN.2008.02.023

Global cancer statistics, 2002

1 reference

5 June 2022

https://opencitations.net/index/coci/api/v1/references/10.1016/J.LUNGCAN.2008.02.023

New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada

1 reference

5 June 2022

https://opencitations.net/index/coci/api/v1/references/10.1016/J.LUNGCAN.2008.02.023

American Society of Clinical Oncology treatment of unresectable non-small-cell lung cancer guideline: update 2003.

1 reference

5 June 2022

https://opencitations.net/index/coci/api/v1/references/10.1016/J.LUNGCAN.2008.02.023

Randomized phase III trial of docetaxel versus vinorelbine or ifosfamide in patients with advanced non-small-cell lung cancer previously treated with platinum-containing chemotherapy regimens. The TAX 320 Non-Small Cell Lung Cancer Study Group.

1 reference

5 June 2022

https://opencitations.net/index/coci/api/v1/references/10.1016/J.LUNGCAN.2008.02.023

TRIBUTE: a phase III trial of erlotinib hydrochloride (OSI-774) combined with carboplatin and paclitaxel chemotherapy in advanced non-small-cell lung cancer.

1 reference

5 June 2022

https://opencitations.net/index/coci/api/v1/references/10.1016/J.LUNGCAN.2008.02.023

Erlotinib in previously treated non-small-cell lung cancer

1 reference

5 June 2022

https://opencitations.net/index/coci/api/v1/references/10.1016/J.LUNGCAN.2008.02.023

Effect of epidermal growth factor receptor tyrosine kinase domain mutations on the outcome of patients with non-small cell lung cancer treated with epidermal growth factor receptor tyrosine kinase inhibitors

1 reference

5 June 2022

https://opencitations.net/index/coci/api/v1/references/10.1016/J.LUNGCAN.2008.02.023

Gefitinib in combination with paclitaxel and carboplatin in advanced non-small-cell lung cancer: a phase III trial--INTACT 2.

1 reference

5 June 2022

https://opencitations.net/index/coci/api/v1/references/10.1016/J.LUNGCAN.2008.02.023

Comparison of four chemotherapy regimens for advanced non-small-cell lung cancer

1 reference

5 June 2022

https://opencitations.net/index/coci/api/v1/references/10.1016/J.LUNGCAN.2008.02.023

Randomized phase III trial of pemetrexed versus docetaxel in patients with non-small-cell lung cancer previously treated with chemotherapy

1 reference

5 June 2022

https://opencitations.net/index/coci/api/v1/references/10.1016/J.LUNGCAN.2008.02.023

Prospective randomized trial of docetaxel versus best supportive care in patients with non-small-cell lung cancer previously treated with platinum-based chemotherapy.

1 reference

5 June 2022

https://opencitations.net/index/coci/api/v1/references/10.1016/J.LUNGCAN.2008.02.023

Gefitinib in combination with gemcitabine and cisplatin in advanced non-small-cell lung cancer: a phase III trial--INTACT 1.

1 reference

5 June 2022

https://opencitations.net/index/coci/api/v1/references/10.1016/J.LUNGCAN.2008.02.023

Phase III study of erlotinib in combination with cisplatin and gemcitabine in advanced non-small-cell lung cancer: the Tarceva Lung Cancer Investigation Trial

1 reference

5 June 2022

https://opencitations.net/index/coci/api/v1/references/10.1016/J.LUNGCAN.2008.02.023

Identifiers

DOI

10.1016/J.LUNGCAN.2008.02.023

1 reference

4 November 2017

1 reference